TABLE 3.
Figure | Strain | mAb pretxt | Incidence | Means (±se) maximal scores (overall) | P | Means (±se) maximal scores (d 20–32) | P | % Maximal weight loss (d20–32) | P |
---|---|---|---|---|---|---|---|---|---|
3G and H | 2D2-FIG | Y13 isotype control | 7 of 7 | 4.3 ± 0.2 | ns | 4.3 ± 0.2 | <0.001 | 28.8 ± 3.4% | 0.027 |
3G and H | 2D2-FIG | Anti-CD25 | 8 of 8 | 4.3 ± 0.2 | ns | 4.3 ± 0.2 | <0.001 | 25.5 ± 1.8% | ns |
3G and H | 2D2-FIG Csf2−/− | Y13 isotype control | 5 of 5 | 3.2 ± 0.4 | * | 1.8 ± 0.2 | * | 14.9 ± 1.9% | * |
3G and H | 2D2-FIG Csf2−/− | Anti-CD25 | 6 of 6 | 3.8 ± 0.3 | ns | 3.8 ± 0.3 | =0.008 | 24.4 ± 4.2% | ns |
These data are portrayed in Fig. 3G and H. 2D2-FIG and 2D2-FIG Csf2−/− mice were injected with PC61 or Y13 (isotype control) on d −4 and −2. All mAb were injected at a dose of 250 µg/mAb/injection. Mice were immunized on d 0 with 200 µg MOG35–55 in CFA with i.p. injections of Ptx on d 0 and 2. Mice were scored and weighed daily until the end of the experiment on d 32. Shown are the mean cumulative and maximal scores (±sem). Asterisk indicates the control group.